ReviewInternal medicine (Tokyo, Japan)2025
Allergic Bronchopulmonary Aspergillosis/Mycosis: An Allergic Disease or an Eosinophilic Disease?
Review in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Advances in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis/Mycosis.Allergy, asthma & immunology research · 2026Review
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Eosinophilic pediatric ABPM lacking fungal sensitization responsive to anti-IL-5.The journal of allergy and clinical immunology. Global · 2026Article
- Allergic bronchopulmonary mycosis caused byIDCases · 2026Article
- Establishment of a novel murine model of allergic bronchopulmonary aspergillosis using an eosinophilic mutant mouse.The Journal of veterinary medical science · 2026Article
- Review
- High sensitization toThe World Allergy Organization journal · 2025Article
- A 48-year-old male with allergic bronchopulmonary aspergillosis: a rare case report.Annals of medicine and surgery (2012) · 2025Article
- Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) is characterized by increased serum levels of total and fungi-specific immunoglobulin E (IgE) and eosinophilic mucus plugs in the airways. Its classification as either an allergic or eosinophilic disease remains controversial. In the present review, we explored this topic based on three clinical studies that analyzed the clinical characteristics of ABPA/ABPM using a cluster analysis, factor analysis, and comparison between ABPM caused by Schizophyllum commune and ABPA. We also compared therapeutic responses to biologics targeting either IgE (omalizumab) or eosinophils (mepolizumab/benralizumab) to elucidate the role of these components in the pathogenesis of ABPA/ABPM. Based on these analyses, eosinophilic mucus plug formation in the airways is considered a cardinal feature of the development of ABPA/ABPM, whereas IgE responses to fungi are important factors that modulate disease manifestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.